HEIP
JAZZ icon

Hudson Edge Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hudson Edge Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed -$2.09K – 144
2024
Q4 		$2.09K Buy
17
+5
+42% +$589 ﹤0.01% 182
2024
Q3 		$1.34K Hold
12
– – ﹤0.01% 195
2024
Q2 		$1.28K Buy
+12
New +$1.32K ﹤0.01% 192

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Hudson Edge Investment Partners's JAZZ Position: Q1 2025 in Review

Hudson Edge Investment Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 17 shares — an estimated $2.09K sold.

Hudson Edge Investment Partners first reported a position in JAZZ in Q2 2024 and held it in 3 quarters. The position peaked at $2.09K in Q4 2024. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Hudson Edge Investment Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Hudson Edge Investment Partners sold 17 Jazz Pharmaceuticals shares in Q1 2025, an estimated $2.09K.
  • Hudson Edge Investment Partners first reported a position in Jazz Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Hudson Edge Investment Partners's Jazz Pharmaceuticals position peaked at $2.09K in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Hudson Edge Investment Partners's 13F filing for Q1 2025, filed 28 Apr 2025.